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Abstract
When grown in 3D cultures as spheroids, mesothelioma cells acquire a multicellular resistance to apoptosis that resembles
that of solid tumors. We have previously found that resistance to the proteasome inhibitor bortezomib in 3D can be
explained by a lack of upregulation of Noxa, the pro-apoptotic BH3 sensitizer that acts via displacement of the Bak/Bax-
activator BH3-only protein, Bim. We hypothesized that the histone deacetylase inhibitor vorinostat might reverse this block
to Noxa upregulation in 3D. Indeed, we found that vorinostat effectively restored upregulation of Noxa protein and
message and abolished multicellular resistance to bortezomib in the 3D spheroids. The ability of vorinostat to reverse
resistance was ablated by knockdown of Noxa or Bim, confirming the essential role of the Noxa/Bim axis in the response to
vorinostat. Addition of vorinostat similarly increased the apoptotic response to bortezomib in another 3D model, the tumor
fragment spheroid, which is grown from human mesothelioma ex vivo. In addition to its benefit when used with
bortezomib, vorinostat also enhanced the response to cisplatin plus pemetrexed, as shown in both 3D models. Our results
using clinically relevant 3D models show that the manipulation of the core apoptotic repertoire may improve the
chemosensitivity of mesothelioma. Whereas neither vorinostat nor bortezomib alone has been clinically effective in
mesothelioma, vorinostat may undermine chemoresistance to bortezomib and to other therapies thereby providing a
rationale for combinatorial strategies.
Citation: Barbone D, Cheung P, Battula S, Busacca S, Gray SG, et al. (2012) Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via
Restoration of Noxa Expression. PLoS ONE 7(12): e52753. doi:10.1371/journal.pone.0052753
Editor: Keiran Smalley, The Moffitt Cancer Center & Research Institute, United States of America
Received August 21, 2012; Accepted November 21, 2012; Published December 26, 2012
Copyright:  2012 Barbone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a TRDRP fellowship to DB (18FT-0120), a Department of Defense Mesothelioma Program grant to VCB (PR080717) and by
the Simmons Mesothelioma Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dario.barbone@ucsf.edu
Introduction
Solid tumors such as mesothelioma are characterized by a
stubborn resistance to chemotherapy, mostly due to resistance to
apoptosis. We have explored the mechanisms of this apoptotic
resistance in 3D spheroids, in which cancer cells acquire a broad
multicellular resistance to apoptosis that may replicate some of the
chemoresistance seen in human solid tumors. Indeed, we have
been encouraged that several of our findings in 3D multicellular
spheroids have been replicated in our studies of human
mesothelioma tumor tissue grown ex vivo [1,2].
Based on our prior studies in both mesothelioma and in lung
cancer, the apoptotic resistance seen in 3D spheroids appeared to
be mediated by alterations in the Bcl-2 family [1,3]. In
mesothelioma cells grown in 3D, the baseline expression of the
Bcl-2 family members and the response of the Bcl-2 proteins to
pro-apoptotic stress differed significantly from that in the same
cells in 2D. One intriguing finding was that the Bak/Bax-activator
BH3-protein Bim was elevated in 3D spheroids compared to 2D
monolayers. Moreover, the bortezomib-mediated increase in
Noxa, the BH3 protein that displaces Bim and thereby mediates
apoptosis, failed to increase. Although we could induce apoptosis
in these spheroids by displacing Bim using a BH3-mimetic (ABT-
737) or by replacing Noxa with a cell permeable R8-Noxa BH3
peptide, we sought a clinically relevant mechanism by which we
could restore the cellular upregulation of Noxa. For this, we tested
a histone deacetylase inhibitor, vorinostat, an agent known to
restore expression of several pro-apoptotic genes, including Noxa,
in resistant settings [4,5].
Vorinostat has been shown to induce apoptosis in many in vitro
studies of solid tumors, including mesothelioma [5,6], largely by
unwinding condensed chromatin and allowing transcription of
epigenetically silenced genes. In addition, HDAC inhibitors such
as vorinostat have modulatory effects on other HDAC substrates,
such as chaperones [7], and can activate immune and inflamma-
tory processes [8]. Unfortunately, despite these promising features,
in a recent large clinical trial of patients with mesothelioma,
vorinostat proved to be ineffective [unpublished, http://goo.gl/
dZCFx]. Similarly, after multiple promising in vitro studies,
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mesothelioma [9]. We, as other groups in the mesothelioma
research field, believe that studying chemoresistance in 3D can
reveal novel mechanisms [10–12]. Hence we wished to use our
resistant 3D models to investigate the activity of each agent alone
and the activity of the two agents in combination. If vorinostat
could restore the ability of bortezomib to upregulate Noxa in our
3D models, then these two agents could potentially be useful in
combination in the clinical setting.
In this report, we show that the histone deacetylase inhibitor
vorinostat eliminated the apoptotic resistance to bortezomib
acquired by 3D spheroids. This was shown to be due to the
ability of vorinostat to restore bortezomib-induced upregulation of
Noxa protein expression in the 3D spheroids. In both 3D models,
multicellular spheroids and tumor fragment spheroids grown from
mesothelioma tumor ex vivo, vorinostat had little apparent
apoptotic effect by itself but acted to enhance the apoptosis
induced by bortezomib. In both spheroid models, vorinostat also
amplified the apoptosis induced by cisplatin plus pemetrexed,
suggesting that vorinostat could improve the response to a variety
of therapeutic approaches.
Materials and Methods
Cell cultures and reagents
The human mesothelioma cell lines M28 and VAMT were
obtained from Dr. Brenda Gerwin [13,14]. The human mesothe-
lioma cell lines REN and SARC (MesoSA1) were obtained from
Dr. Steven Albelda [15] and from Dr. Alice Boylan [16],
respectively. All cells were cultured in DMEM supplemented with
10% FBS and 100 IU/mL penicillin/streptomycin in a 37uC
humidified incubator with 5% CO2 (full DMEM).
A standard dose of bortezomib (100 nM) was used for short-
term experiments such as western blots and qRT-PCR. A lower
dose (25 nM) was used in all apoptotic assays at 24 h. Vorinostat
(ZolinzaH) was from Selleck Chem (Boston, MA). Bortezomib
(VelcadeH) was from Millennium Pharmaceuticals (Cambridge
MA). Cisplatin and pemetrexed were obtained from the UCSF
Pharmacy at Mt. Zion Cancer Center.
Generation and treatment of spheroids
Multicellular spheroids were generated in non-adsorbent round-
bottomed 96-well plates, as described [17]. The 96-well plates
were coated with a 1:24 dilution of polyHEMA (120 mg/ml)
(#P3932 Sigma-Aldrich, St. Louis, MO) in 95% ethanol and dried
at 37uC for 24 h. Before use, plates were sterilized by UV light for
30 min. For generation of multicellular spheroids, 10
4 cells were
added into each well of polyHEMA-coated 96-well plate. The
plates were briefly spun for 5 min at 800 rpm and then placed in a
37uC humidified incubator with 5% CO2 for 48 h. For generation
of monolayers, 180,000 cells were added into each well of 6-well
plates. Bright field images were taken with a Zeiss Invertoskop
40C.
Tumor Fragment Spheroids were generated as previously described
[2] from six tumor samples obtained from extrapleural pneumo-
nectomy (EPP) or pleurectomy procedures performed by D.J.S.
and R.B. at Brigham and Women’s Hospital in Boston, MA USA.
A part of the tumor was fixed in 10% formalin (Fisher Scientific,
Fair Lawn, NJ) and embedded in paraffin. For spheroid culture,
tumor tissue was diced finely with scalpels to pieces smaller than
1 mm in diameter that were suspended in medium in 10-cm plates
coated with 0.8% agar (Agar Noble, #A5431 Sigma-Aldrich, St.
Louis, MO) in full DMEM. The volume of overlay media was
15 ml, and half the volume of the overlay media was changed
twice a week. The agar-coated plates were regularly observed
using an inverted phase microscope during the incubation period,
up to 4 weeks. Spheroids were collected at different time points,
treated as described in figure legends, fixed in 10% formalin, and
embedded in paraffin for immunostaining.
Treatment. Before treatment, 18 multicellular spheroids (or
20–30 tumor fragment spheroids) were transferred to each well of
a polyHEMA-coated 24-well plate to match the numbers of cells
plated as monolayers (180,000 cells per well). The spheroids and
monolayers were treated with apoptotic agents in full DMEM with
or without inhibitors (and the appropriate DMSO vehicle control)
for 24 h.
Immunoblotting
After treatment, monolayers and spheroids were lysed in boiling
lysis buffer (2.5% SDS, Tris-HCl 250 mM pH 7.4). The
concentration of total protein was evaluated with a colorimetric
assay (DC protein assay from BioRad, Hercules, CA). 50 mg of cell
lysates were loaded in reducing conditions (0.2 M Tris, pH 6.8,
5% SDS, 3% glycerol, 0.01% bromophenol blue and 200 mM
DTT). After separation in SDS-PAGE (5 to 15% acrylamide) and
transfer to PVDF (Immobilon, Millipore, Billerica, MA), mem-
branes were blocked with a protein-free TBS blocking buffer
(Pierce, Rockford, IL) and gently agitated with antibodies diluted
in 5% non-fat dry milk or 5% BSA, as appropriate, at 4uC
overnight. Secondary antibodies were from Amersham (Piscat-
away, NJ). Chemiluminescence was detected with the enhanced
SuperSignal West Pico Substrate (Pierce, Rockford, IL) with a
Biospectrum Imaging System (UVP, Upland, CA). The antibody
against Bim (#559685) was from BD Pharmingen (San Jose, CA)
and the Noxa antibody was from Calbiochem (#OP180). The a-
tubulin antibody (#T-6074) was from Sigma-Aldrich (St. Louis,
MO). Densitometry of the bands was analyzed with the Vision-
WorksLS software (UVP, Upland, CA). Total raw pixel density of
each band was normalized to its respective tubulin band and
expressed as a ratio.
Co-immunoprecipitation
Spheroids (100 for each condition) were treated as indicated and
lysed in ice-cold CHAPS buffer (1% (w/v) CHAPS, 10 mm
HEPES pH 7.4, 150 mm NaCl) plus protease inhibitor cocktail
and EDTA (Pierce, Rockford, IL) for 30 min. Lysates were then
centrifuged at 15,000 rpm for 15 min at 4uC. 500 mg of the
cleared lysates were pre-incubated at 4uC for 1 h with 50 mlo fa
50:50 slurry of CHAPS buffer and Sepharose Prot G (Amersham,
Piscataway, NJ). Pre-cleared lysates were then incubated with the
Mcl-1 antibody (Santa Cruz, SC-189, 2 mg per condition) for 1 h
at 4uC. 50 ml of a 50:50 slurry of CHAPS buffer and Sepharose
Prot G (Amersham, Piscataway, NJ) were added, and lysates were
incubated overnight at 4uC to capture the immune complexes.
Beads were then washed five times with ice-cold CHAPS buffer
and bound proteins were eluted with 50 ml of a low pH elution
buffer (#1858606, Pierce, Rockford, IL). Recovered lysates were
neutralized by addition of 5 ml of Tris-HCl 1.5 M pH 8.8 and
boiled for 5 min with Laemmli Buffer (glycerol 10%, bromophenol
blue 1%, dithiothreitol (DTT) 1 M, SDS 10%, Tris-Cl 1 M,
pH 6.8). Immunoblotting was performed as described above.
RNA interference
Cells (4610
6) were pelleted and resuspended in 100 mlo f
nucleofection buffer (solution T, Amaxa Biosystems, Cologne,
Germany) with 1.5 mg of the appropriate siRNA duplex (Ambion,
Austin, TX). This suspension was transferred to a sterile cuvette
and nucleofected using program T-20 on a Nucleofector II device
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complete DMEM medium, the cells were plated and allowed to
grow for 24 h. Cells were then trypsinized, counted and plated as
monolayers and spheroids for 24 h, and exposed to apoptotic
stimuli. The siRNA sequences were: Bim (ACUUACAUCA-
GAAGGUUGCtt), Noxa (GAAAUGUGUCAAUAAUUACtt),
non-targeting control (GCAACCUUCUGAUGUAAGUtt). Cells
transfected with siRNA were also allowed to form into spheroids,
treated with bortezomib and subjected to immunoblotting to
determine if Noxa and Bim were effectively ablated.
Measurement of apoptosis in multicellular spheroids
Nuclear condensation. Apoptosis was quantitated by count-
ing cells with nuclear condensation. Monolayers and spheroids
were disaggregated by exposure to trypsin for the same period of
time, washed with ice-cold PBS, and then fixed with 2.5%
glutaraldehyde (Sigma-Aldrich, St. Louis, MO). The cells were
then stained with 8 mg/ml of Hoechst 33342 (Molecular Probes,
Invitrogen, Carlsbad, CA) and placed on slides. Apoptosis was
quantitated by counting cells with distinctive signs of nuclear
condensation and expressed as a % of the total cells. For each
condition, at least 300 cells were counted in triplicate by
investigators blinded to the experimental conditions.
Caspase activation. Apoptosis was also measured by an
assay of caspase activation, by use of a Caspase-GloH 3/7 assay kit
(Promega, Madison WI). In this assay, the level of caspase activity
is measured by the caspase-3/7 mediated cleavage of a
proluminescent caspase-3/7 substrate, which releases a substrate
for luciferase and thereby produces light. Briefly, spheroids were
treated as indicated in the polyHEMA-coated 96 wells in which
they were grown (200 ml final volume). One spheroid was used for
each condition; studies were performed in quadruplicate. After
treatment, plates were spun at 400 g for 10 min RT; 100 mlo f
supernatant was carefully removed without disturbing the pellet
and 100 ml of complete CaspaseGloH 3/7 reagent was added to
each well. Plates were gently mixed using a plate shaker at 300–
500 rpm for 1 min and then incubated at RT away from light for
1 h. Sample luminescence was measured in a plate-reading
luminometer (Perkin Elmer, Waltham, MA).
Measurement of apoptosis in tumor fragment spheroids
Measurement of apoptosis in this complex tissue required dual
immunostaining to identify the mesothelioma cells and thus to
localize the cleaved caspase 3 characteristic of apoptosis to the
mesothelioma cells, as we have previously reported [18]. Following
treatment, tumor fragment spheroids were collected, fixed in 10%
buffered formalin in PBS overnight at 4uC and embedded in 3%
agar in PBS. The agar pellets containing the tumor fragment
spheroids were further embedded in paraffin blocks by the UCSF
pathology core at SFGH. For immunostaining, 5 mm paraffin
sections were deparaffinized with Xylene (265 min), 100% EtOH
(262 min), 95% EtOH (262 min), 70% EtOH (262 min), 50%
EtOH (162 min) and ddH20 (262 min). Endogenous peroxidases
were blocked with a solution of 250 ml MeOH +5 ml 30% H202
for 20 min. Antigens were retrieved in citrate buffer (Citra,
BioGenex; #HK087-5K) in a microwave oven set to high for 7–
8 min. Sections were blocked with 5% normal goat serum, 2.5%
BSA in PBS for 30–45 min in a humidified chamber at RT.
Primary antibodies for cleaved caspase 3 (1:100, Chemicon;
#AB3623) and pan-cytokeratin (1:100, Progen, Heidelberg,
Germany; clone GP14) were incubated in a humidified chamber
at 4uC overnight. The secondary antibodies donkey anti-rabbit
AlexaFluor 488 (Pierce, Rockford, IL; #31821) and anti-guinea
pig AlexaFluor 633 (Invitrogen, Carlsbad, CA; #A-21105), both
1:200, were incubated for 30–45 min at RT in a humidified
chamber. Slides were washed 3 times in PBS for 3 min and
mounted with Vectashield. In a blinded fashion, the investigators
examined images of doubly stained cells in the tumor fragment
spheroids. Apoptotic mesothelioma cells were considered to be
cells with merged red (pan-cytokeratin) and green (cleaved caspase
3) and were expressed as a percentage of the total number of
mesothelioma cells (red). For each condition, 3–10 spheroids were
counted until a total of 300 mesothelioma cells were visualized.
Immunohistochemistry of tumor fragment spheroids
New sections were cut from the paraffin blocks of the tumor
fragment spheroids used for the apoptosis studies described above
and were probed for expression of Bim and Noxa protein by
immunohistochemistry. 5 mm paraffin sections were stained using
a Bim antibody (#559685BD, Pharmingen, San Jose, CA - 1:200,
2h ,4 uC) and a Noxa antibody (#OP-180, Calbiochem – 1:200,
2h ,4 uC) and visualized with a HRP/DAB Envision plus Kit
(#K4010, Dako, Carpinteria, CA). Hematoxylin was used as a
counterstain.
Real-Time quantitative polymerase chain reaction
M28 or REN cells (10
6) were plated as monolayers or spheroids
(100 spheroids – 10
4 cells/spheroid) and RNA was extracted with
an RNeasy Kit following manufacturer’s instructions (Qiagen,
Valencia, CA). Extracted total RNA was quantified with a
NanoDrop 2000c (NanoDrop, Wilmington, DE) and 2 mg of total
RNA was retro-transcribed with a SuperscriptH VILO cDNA
Synthesis Kit (Life Technologies, Carlsbad, CA). A TaqManH
Gene Expression Analysis Assay (Life Technologies, Carlsbad,
CA) was performed according to manufacturer’s instructions in a
ABI 7000 thermal cycler (Life Technologies, Carlsbad, CA).
Taqman probes for Noxa (Hs00560402_m1), Bim
(Hs01076940_m1), Bmf (Hs00372937_m1) and the control beta
glucuronidase (GUSB 4333767T) were from Applied Biosystems
(Life Technologies, Carlsbad, CA). Calculations for determining
the relative levels of gene expression were made from triplicate
measurements of the target gene, with normalization to GUSB in
the samples, using the cycle threshold (Ct) method and the 2
2DDct
equation [19].
Statistical analysis
Data are expressed as mean 6 one standard deviation of at least
three different experiments. Statistical significance was evaluated
by one or two-way analysis of variance, and Tukey’s test was
performed to detect where the differences lay (GraphPad Prism
version 4.0, GraphPad Software, Inc.). A p value less than 0.05
was considered significant.
Results
Vorinostat eliminates multicellular resistance of
spheroids
Four mesothelioma cell lines (M28, REN, SARC and VAMT)
were grown as 2D monolayers or 3D spheroids and treated with
the proteasome inhibitor bortezomib, As expected, all cell lines
grown as 3D spheroids demonstrated multicellular apoptotic
resistance to bortezomib. Remarkably, in all four lines, when
vorinostat was added in combination with bortezomib, vorinostat
effectively abolished the multicellular resistance to bortezomib, as
shown by the restoration of apoptosis in the cells in 3D to the same
or greater level as that seen in 2D (Figure 1A–D). When given
alone, however, vorinostat did not induce apoptosis in either
monolayers or spheroids (Figure 1A–D). A second assay of
Vorinostat and Mesothelioma 3D Spheroids
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52753Figure 1. Vorinostat abolishes multicellular resistance of spheroids. (A) Four mesothelioma cell lines (M28, REN, SARC and VAMT) were
grown as monolayers and spheroids and treated with bortezomib (25 nM), vorinostat (5 mM) or their combination for 24 h. Apoptosis was measured
by analysis of nuclear condensation in Hoechst-stained cells. Spheroids grown from all the cell lines acquired multicellular resistance to bortezomib, a
resistance that was effectively eliminated by the addition of vorinostat. Both vorinostat and bortezomib induced little apoptosis in spheroids when
given alone. (* p,0.05 as compared to bortezomib alone, n=3) (B) Apoptosis was confirmed by CaspaseGlo 3/7 assay in M28 and REN spheroids,
treated with either bortezomib (25 nM), vorinostat (5 mM) or their combination for 24 h. Vorinostat had no effect on spheroids but increased their
apoptotic response to bortezomib (* p,0.05 as compared to bortezomib or vorinostat alone, n=3) (C–D) Bright field 106images of the edge of M28
and REN spheroids treated with vorinostat, bortezomib or the combination for 24 h. Whereas vorinostat or bortezomib alone induced little or no
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vorinostat alone had no effect but, when given in combination
with bortezomib, effectively increased apoptosis of cells in 3D
spheroids (Figure 1B). Vorinostat alone had no evident effect on
the morphology of spheroids (Figure 1C–D) however, when
given with bortezomib, vorinostat clearly amplified the morpho-
logic alterations seen with bortezomib. The floating cells, shown as
detached from spheroids, were all found to be non-viable (data not
shown). As seen with bortezomib, vorinostat also amplified the
apoptotic response to cisplatin plus pemetrexed, the standard
treatment used for patients with mesothelioma [20] (Figure S1).
Vorinostat restores bortezomib-induced increase of Noxa
protein and mRNA in 3D
Our previous studies identified a lack of Noxa upregulation in
3D mesothelioma spheroids as a cause of multicellular resistance
to bortezomib [1]. To confirm if vorinostat restored Noxa
upregulation, we analysed its protein and mRNA expression in
M28 and REN cells treated with bortezomib, with or without
vorinostat, and harvested at 4–6 h before the onset of apoptosis.
Upon treatment with bortezomib, Noxa protein expression
increased in the cells in 2D; however, as previously observed, this
increase was either not seen or was much reduced in 3D spheroids
(Figure 2 – densitometry analysis in Figure S2A and S2B).
When used alone, vorinostat had little effect on Noxa protein
expression; however, when used in combination with bortezomib,
vorinostat significantly increased Noxa expression in both 2D and
3D. In the 3D spheroids, Noxa either reached the level seen after
bortezomib alone in 2D (REN) or exceeded it (M28). Because
Noxa is reported to act via the displacement of Bim from anti-
apoptotic reservoirs, we also investigated changes in Bim
expression. Vorinostat alone and particularly in combination with
bortezomib increased Bim in mesothelioma cells in both 2D and
3D. Vorinostat also increased expression of Noxa and Bim in
spheroids when used in combination with cisplatin plus peme-
trexed (Figure S3).
We examined the transcription of Noxa message to determine
whether it was suppressed in 3D and whether vorinostat restored
transcription. Indeed, after bortezomib, Noxa message increased
in cells grown in 2D but did not increase significantly in cells in 3D
(Figure 3). Vorinostat appeared to remove the suppression of
Noxa transcription in 3D; after the combination of vorinostat with
bortezomib, Noxa message increased to the same extent in cells in
3D as in 2D.
In addition to Noxa and Bim, Bmf has been reported to respond
to vorinostat (10) and possibly to activate Bax/Bak directly (11).
However, we found that Bim and Bmf message increased no more
than 2–3 fold whereas Noxa message increased by 10–20 fold
following the combination of vorinostat plus bortezomib (Figure
S4).
morphologic change, the combination potently increased the number of cells detaching from the spheroids and floating in the medium. (Focus was
adjusted in the lower panels to visualize some of these floating cells).
doi:10.1371/journal.pone.0052753.g001
Figure 2. Vorinostat restores the upregulation of Noxa induced
by bortezomib in spheroids. M28 and REN monolayers and
spheroids were treated with bortezomib (100 nM), vorinostat (5 mM)
or the combination for 6 h. Cells were then lysed and Noxa and Bim
levels were analyzed by immunoblot. In both M28 and REN cells grown
as monolayers, bortezomib increased levels of Noxa protein; however,
in the same cells grown as spheroids, the bortezomib-induced increase
in Noxa was blunted or absent. With the addition of vorinostat,
bortezomib now increased Noxa protein in the spheroids to levels
comparable to or greater than those in bortezomib-treated monolayers.
Of note, vorinostat alone had little or no effect on Noxa protein levels.
Vorinostat alone and particularly in combination with bortezomib
increased the levels of Bim protein. (Densitometry of band intensities
relative to tubulin is shown in Figure S2A and S2B).
doi:10.1371/journal.pone.0052753.g002
Figure 3. Vorinostat restores Noxa mRNA of spheroids to the
level of monolayers. M28 and REN monolayers and spheroids were
treated with bortezomib (100 nM), vorinostat (5 mM) or their combina-
tion for 4 h and Noxa mRNA was measured by qRT-PCR. After treatment
with bortezomib, Noxa mRNA increased significantly in monolayers but
was significantly lower in spheroids. The addition of vorinostat to
bortezomib led to an increase in Noxa mRNA levels in spheroids to the
same level as in monolayers. (* p,0.05, significant increase compared
to bortezomib alone; { p,0.05, significantly less than in the monolayer
exposed to same treatment; n=3).
doi:10.1371/journal.pone.0052753.g003
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Noxa has been shown to bind primarily to the anti-apoptotic
protein Mcl-1, where it can displace Bim, thereby allowing Bim to
mediate apoptosis by activating Bax and Bak [21]. To verify that
the Noxa upregulated by vorinostat displaces pro-apoptotic Bim
from Mcl-1, we performed a co-immunoprecipitation to measure
the change in the amount of Noxa and Bim bound to Mcl-1 upon
vorinostat (Figure 4). Following treatment with either vorinostat
or bortezomib alone, there was a slight increase in the amount of
Noxa bound to Mcl-1 but no apparent change in the binding of
Bim. However, following the use of vorinostat together with
bortezomib, there was an increased amount of Noxa bound to
Mcl-1 and a reduced binding of Bim, confirming displacement of
Bim.
To confirm that the restored Noxa plays an essential role in the
ability of vorinostat to reduce multicellular resistance, we ablated
Noxa by siRNA before treating spheroids with bortezomib with or
without vorinostat (Figure 5). In the absence of Noxa, vorinostat
failed to increase bortezomib-induced apoptosis in 3D, thereby
confirming a requirement for Noxa in the pro-apoptotic activity of
vorinostat. We then asked whether Bim was also required for the
activity of vorinostat. Indeed, in the absence of Bim, vorinostat
also failed to enhance bortezomib-induced apoptosis in 3D. Thus,
vorinostat acts via both Noxa and Bim in the elimination of
multicellular resistance and the restoration of apoptosis in response
to bortezomib.
Vorinostat enhances the apoptotic response of
mesothelioma cells in ex vivo tumor fragment spheroids
We then asked whether vorinostat would also increase
chemoresponsiveness of mesothelioma cells within tumor fragment
spheroids derived from human mesothelioma tissue. In this model,
the mesothelioma cells reside in a complex tumor microenviron-
ment [18] and represent a heterogeneous ex vivo tumor population.
We used tumor fragments from six different mesothelioma
tumors and treated them with bortezomib (n=3) or cisplatin plus
pemetrexed (n=3), with or without vorinostat. When used alone,
vorinostat, bortezomib or cisplatin plus pemetrexed failed to
induce a significant increase in apoptosis of mesothelioma cells.
However, when vorinostat was added together with bortezomib or
with cisplatin plus pemetrexed, mesothelioma cells in the tumor
fragment spheroids from each tumor underwent a significant
increase in apoptosis (Figure 6A–B). To assess whether vorinostat
increased Noxa and Bim in the tissue, we stained the tumor
fragment spheroids treated with vorinostat with or without
chemotherapy. In the tumor fragment spheroids from all 3 tumors
treated with vorinostat plus cisplatin and pemetrexed, Noxa and
Bim protein expression increased (Figure 6C–D).
Discussion
Solid tumors such as mesothelioma exhibit a resistance to
chemotherapy that poses a challenge for curative therapy. We
have attempted to model this chemoresistance in our 3D models,
in which cells acquire multicellular resistance. Previously, we have
reported that the acquired multicellular resistance is mediated by
alterations in the Bcl-2 family of proteins, raising the hope that
strategies directed to the Bcl-2 family could undermine resistance
[1]. In this study, we have found that a broadly active histone
deacetylase inhibitor, vorinostat, is able to ablate the multicellular
resistance to bortezomib by its ability to restore expression of a key
pro-apoptotic Bcl-2 family member, Noxa.
In our previous work in 3D spheroids, resistance to bortezomib
was shown to be due to a lack of upregulation of Noxa, a sensitizer
BH3-only protein that acts via displacement of pro-apoptotic Bim
from Mcl-1 and possibly also from Bcl-2 and Bcl-xl [1,22,23].
Importantly, we found that spheroids expressed elevated Bim and
were primed for apoptosis but, without Noxa to displace the Bim
from anti-apoptotic buffers, the spheroids exhibited a resistance to
Figure 4. Noxa, when upregulated by vorinostat, binds to Mcl-
1 and displaces pro-apoptotic Bim. M28 spheroids were treated
with bortezomib (100 nM), vorinostat (5 mM) or their combination for
4 h, then studied by co-immunoprecipitation for Mcl-1 binding
partners. Both vorinostat and bortezomib alone slightly increased the
amount of Noxa bound to Mcl-1 but did not change the amount of
bound Bim. However, the combination of vorinostat and bortezomib
increased the amount of Noxa bound to Mcl-1 to a greater extent and
reduced the amount of bound Bim. As expected, bortezomib increased
total Mcl-1 slightly; nonetheless, the elevated Noxa was apparently
sufficient to displace Bim.
doi:10.1371/journal.pone.0052753.g004
Figure 5. Noxa and Bim are each required for vorinostat to
increase the apoptotic response of spheroids. REN cells were
treated with siRNA to ablate Noxa or Bim, allowed to form spheroids
over 24 h and then treated with bortezomib, vorinostat or the
combination. Monolayers were treated similarly for 4 h and collected
and lysed to verify the efficacy of Noxa siRNA (see immunoblots). After
24 h, Hoechst-stained cells were counted for the presence of apoptosis.
Noxa and Bim siRNA significantly inhibited the ability of vorinostat to
increase apoptosis in spheroids. (* p,0.05, significant difference
compared to control siRNA; n=3).
doi:10.1371/journal.pone.0052753.g005
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the upregulation of Noxa in the spheroids and turned to
vorinostat, an HDAC inhibitor thought to act via enhanced
transcription and expression of epigenetically-silenced genes, many
of which are pro-apoptotic [24]. Indeed, vorinostat effectively
restored the pro-apoptotic Noxa upregulation seen in response to
bortezomib. By RNA silencing, Noxa and Bim were each shown
to be required for the ability of vorinostat to undermine
multicellular resistance. Vorinostat appeared to act at least in
part via the transcriptional upregulation of Noxa; in 3D, the
increase in Noxa message in response to bortezomib was blunted
and, with the addition of vorinostat, the Noxa message was
restored to the same levels seen in monolayers. In addition to its
beneficial effect on Noxa regulation, vorinostat increased baseline
levels of Bim protein, in both multicellular spheroids and tumor
fragment spheroids, suggesting that vorinostat could perhaps
elevate Bim in tumors with low Bim, found to represent
approximately 30% of mesotheliomas [1].
Our findings may have clinical relevance for the use of HDAC
inhibitors in combinatorial therapy. Despite promising in vitro and
pre-clinical results, vorinostat and bortezomib have each been
found to be largely ineffective as single agents in clinical trials of
patients with relapsed mesothelioma [unpublished, http://goo.gl/
dZCFx] [9]. Our results in 3D spheroids are similar: neither agent
was effective in inducing apoptosis in 3D spheroids when given
alone. In particular, vorinostat alone had almost no apparent
effect against mesothelioma cells in 3D spheroids; there was no
evident impact of vorinostat alone on cellular morphology, Noxa
transcription, Noxa protein levels or apoptosis. In our models, the
benefit of vorinostat was only seen when it was used with other
agents. Indeed, in clinical trials, whereas vorinostat as a single
agent has yielded disappointing results, its use in combination with
chemotherapy has been reported to have positive results in a
variety of solid and hematological malignancies [25]. It is of
interest then that, despite the lack of benefit reported for vorinostat
as a single agent in mesothelioma, another HDAC inhibitor,
valproic acid, was recently found to have benefit when used with
doxorubicin in mesothelioma patients [26]. Our findings in
mesothelioma lead us to believe that the key to clinical efficacy
of HDAC inhibition lies in its ability to potentiate responses to
chemotherapy [27], a potentially valuable strategy against
chemoresistant solid tumors. Recently, it has been reported that
resistance to manipulation of Noxa can develop over a period of
10 days [28]. Although we did not study our spheroids for that
duration, we saw no resistance to vorinostat over 2 days (data not
shown). Issues including drug resistance as well as drug penetrance
and toxicity will be important considerations in the use of this
combination in the clinic [29].
In summary, we have used 3D models to show the value of
histone deacetylase inhibition in undermining multicellular resis-
tance to chemotherapy. This raises the possibility that the
resistance of the tumor cells in 3D, which can be localized to
the Bcl-2 family, is mediated via epigenetic mechanisms. In the 3D
resistant setting, chemoresponsiveness can be enhanced by either
targeting the Bcl-2 family directly, as we have previously done by
using small molecules such as ABT-737 [1] or indirectly, by
restoring transcription of silenced pro-apoptotic genes, as we show
here. Possibly both strategies could be used together, especially if
vorinostat enhances Bim expression in tumors with low baseline
expression. These studies may provide the basis for the use of these
agents in combination in future clinical trials.
Supporting Information
Figure S1 Vorinostat increases apoptotic response of
spheroids to cisplatin plus pemetrexed. M28 and REN
spheroids were treated with cisplatin (250 mM) plus pemetrexed
(10 mM), vorinostat (5 mM) or their combination for 24 h.
Apoptosis was measured by CaspaseGlo 3/7 assay. Cisplatin plus
pemetrexed (C+P) or vorinostat alone had no effect on spheroids
but the combination induced a significant apoptotic response (*
p,0.05 as compared to cisplatin plus pemetrexed or vorinostat
alone, n=3)
(TIFF)
Figure S2 Densitometry analysis for bands shown in the
western blot in Figure 2: M28 (A) and REN (B). Intensity of
each band was determined by densitometry and expressed relative
to the intensity of the corresponding alpha-tubulin band.
(TIFF)
Figure 6. Vorinostat increases the apoptotic response of
mesothelioma cells within tumor fragment spheroids to
treatment. (A) Tumor fragment spheroids were grown from six
treatment-naı ¨ve mesothelioma samples: three were treated with
bortezomib (100 nM) and three with cisplatin (250 mM) plus peme-
trexed (10 mM) (C+P) with or without vorinostat (5 mM) for 24 h.
Apoptosis was measured by the detection of merged cytokeratin and
cleaved caspase 3 immunofluorescence. In all samples, vorinostat
increased the apoptotic response of mesothelioma cells to treatment. (*
p,0.05 compared to chemotherapy or vorinostat alone, n=3). (B)
Representative confocal fluorescent merged images of tumor fragment
spheroids after treatment. Addition of vorinostat either to bortezomib
or to cisplatin plus pemetrexed increased the number of apoptotic
mesothelioma cells (positive for both pan-cytokeratin and for cleaved
caspase-3 staining). White arrowheads highlight some of the apoptotic
cells. Images are representative of all tumor fragment spheroids used in
the experiment. Immunohistochemistry for Noxa (C) and Bim (D)
showed that the addition of vorinostat to treatment increases both
Noxa and Bim in tumor fragment spheroids (images representative of
the 3 tumor fragment spheroids treated with C+P in panel A).
doi:10.1371/journal.pone.0052753.g006
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Bim induced by cisplatin plus pemetrexed in spheroids.
M28 and REN spheroids were treated with cisplatin (250 mM) plus
pemetrexed (10 mM) (C+P) (alone or with vorinostat (5 mM)) for
6 h. Cells were then lysed and Noxa and Bim levels were analyzed
by western-blot. The addition of vorinostat increased the Noxa
and Bim response to cisplatin plus pemetrexed.
(TIFF)
Figure S4 Vorinostat in combination with bortezomib
increases Noxa message more than that of Bim or Bmf.
M28 and REN spheroids were treated with bortezomib (100 nM)
plus vorinostat (5 mM) for 4 h. Noxa, Bim and Bmf mRNA levels
were determined by qRT-PCR. Noxa mRNA levels increased
more than that of Bim or Bmf.
(TIFF)
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